Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter

被引:32
作者
Telbisz, Agnes [1 ,2 ]
Hegedus, Csilla [1 ,2 ]
Ozvegy-Laczka, Csilla [1 ,2 ]
Goda, Katalin [3 ]
Varady, Gyorgy [1 ,2 ]
Takats, Zoltan [4 ]
Szabo, Eszter [4 ]
Sorrentino, Brian P. [5 ]
Varadi, Andras [6 ]
Sarkadi, Balazs [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Biophys, Hungarian Acad Sci, Membrane Res Grp, H-1113 Budapest, Hungary
[2] Natl Blood Ctr, H-1113 Budapest, Hungary
[3] Univ Debrecen, Dept Cell Biol, Debrecen, Hungary
[4] 1 Semmelweis Univ, Dept Pediat, Budapest, Hungary
[5] St Jude Childrens Res Hosp, Memphis, MS USA
[6] Hungarian Acad Sci, Inst Enzymol, Budapest, Hungary
关键词
Human ABCG2 multidrug transporter; Anti-ABCG2 monoclonal antibody; Drug interactions with ABCG2; Inhibitors of ABCG2; High-throughput antibody shift assay; CANCER RESISTANCE PROTEIN; P-GLYCOPROTEIN; SUBSTRATE-SPECIFICITY; MONOCLONAL-ANTIBODY; KINASE INHIBITORS; BCRP1; ABCG2; BCRP1/ABCG2; METABOLISM; ABSORPTION; MUTATIONS;
D O I
10.1016/j.ejps.2011.10.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ABCG2 multidrug transporter protein has been identified as a key player in cancer drug resistance and xenobiotic elimination, as its actively transported substrates include anticancer drugs, intermediates of home metabolism, xenobiotics, and also drug conjugates. Several transported substrates at higher concentrations, and some anticancer agents even at low concentrations directly inhibit the ABCG2 transporter, thus it is difficult to provide estimation for pharmacologically important ABCG2-dependent interactions. In addition, as documented here, in mutant variants of the transporter, inhibitors of the wild-type ABCG2 may become actively transported substrates. In this paper we describe a rapid in vitro assay to identify transport modulation by measuring the cell surface interaction of a conformation sensitive monoclonal antibody (503) with ABCG2 in intact cells. As documented, in conjunction with membrane ATPase, transport and cytotoxicity measurements, this assay provides a reliable estimate of concentration-dependent modulation of ABCG2 by newly emerging pharmacophores. A high-throughput, 96-well plate assay platform is also provided. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 46 条
[1]   Flavonoid structure-activity studies identify 6-prenyichrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2 [J].
Ahmed-Belkacem, A ;
Pozza, A ;
Muñoz-Martínez, F ;
Bates, SE ;
Castanys, S ;
Gamarro, F ;
Di Pietro, A ;
Pérez-Victoria, JM .
CANCER RESEARCH, 2005, 65 (11) :4852-4860
[2]   Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein [J].
Al-Shawi, MK ;
Polar, MK ;
Omote, H ;
Figler, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (52) :52629-52640
[3]  
Allen JD, 2002, MOL CANCER THER, V1, P427
[4]  
Allen JD, 2002, CANCER RES, V62, P2294
[5]   The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1) [J].
Ambudkar, SV ;
Kim, IW ;
Sauna, ZE .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 27 (05) :392-400
[6]   The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients [J].
Breedveld, P ;
Pluim, D ;
Cipriani, G ;
Wielinga, P ;
van Tellingen, O ;
Schinkel, AH ;
Schellens, JHM .
CANCER RESEARCH, 2005, 65 (07) :2577-2582
[7]   Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter [J].
Clark, R. ;
Kerr, I. D. ;
Callaghan, R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 149 (05) :506-515
[8]   Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A [J].
Ejendal, KFK ;
Hrycyna, CA .
MOLECULAR PHARMACOLOGY, 2005, 67 (03) :902-911
[9]   Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) [J].
Elkind, NB ;
Szentpétery, Z ;
Apáti, A ;
Özvegy-Laczka, C ;
Várady, G ;
Ujhelly, O ;
Szabó, K ;
Homolya, L ;
Váradi, A ;
Buday, L ;
Kéri, G ;
Német, K ;
Sarkadi, B .
CANCER RESEARCH, 2005, 65 (05) :1770-1777
[10]   Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design [J].
Giri, Nagdeep ;
Agarwal, Sagar ;
Shaik, Naveed ;
Pan, Guoyu ;
Chen, Ying ;
Elmquist, William F. .
DRUG METABOLISM AND DISPOSITION, 2009, 37 (03) :560-570